Transcode Therapeutics Inc Stock Price, News & Analysis

TransCode Therapeutics (NASDAQ: RNAZ) has published a study in Oncotarget demonstrating the efficacy of its lead therapeutic candidate, TTX-MC138, against metastatic cancer. The research, conducted in collaboration with Michigan State University, reveals that TTX-MC138 reduces tumor cell capacity for self-renewal by targeting miR-10b, a molecule expressed in stem-like breast cancer cells.

Key findings include:

• Stem-like breast cancer cells increase expression of miR-10b
• TTX-MC138 treatment reduces cancer cell stemness
• Cancer cell stemness is important for metastasis and tumor formation

This study provides insights into TTX-MC138's mechanisms, potentially aiding in predicting clinical responses, defining molecular biomarkers, and improving patient stratification for future clinical trials.

TransCode Therapeutics (NASDAQ: RNAZ) has been awarded a $2 million Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to support the clinical evaluation of its lead therapeutic candidate, TTX-MC138. The grant, awarded by the National Cancer Institute (NCI), will be disbursed over two years.

TransCode has recently activated three clinical trial sites for a Phase I/II clinical trial of TTX-MC138 for treating advanced solid tumors. The trial aims to assess the safety of TTX-MC138 and may provide early evidence of its clinical activity in patients with metastatic disease. TTX-MC138 is described as a first-in-class therapeutic candidate with novel relevance to metastatic disease, potentially offering a viable treatment option for many metastatic cancer patients.

TransCode Therapeutics (NASDAQ: RNAZ) has initiated its Phase 1 clinical trial for TTX-MC138, its lead RNA therapeutic candidate for cancer treatment. Two clinical trial sites have been activated, with patient enrollment expected to begin this quarter. The trial, designed to evaluate the safety and preliminary anti-tumor activity of TTX-MC138, may include up to five sites in total.

The study comprises a dose-escalation phase followed by a dose-expansion phase. It aims to assess the safety, tolerability, and potential clinical activity of TTX-MC138 in patients with various metastatic solid cancers. This marks a significant milestone for TransCode in advancing RNA therapeutics in oncology.

TransCode Therapeutics (Nasdaq: RNAZ), a clinical-stage RNA oncology company, has closed its previously announced public offering. The company sold 10,000,000 shares of common stock at $0.30 per share, raising $3,000,000 in gross proceeds before deducting fees and expenses. TransCode plans to use the net proceeds for product development activities, including clinical trials for its lead therapeutic candidate TTX-MC138, related IND enabling studies, and general corporate purposes. ThinkEquity acted as the sole placement agent for the offering, which was made pursuant to an effective shelf registration statement filed with the SEC.

TransCode Therapeutics (Nasdaq: RNAZ), an RNA oncology company, has announced the pricing of a public offering of 10,000,000 shares of common stock at $0.30 per share. The offering is expected to raise $3,000,000 in gross proceeds and close on July 24, 2024. The company plans to use the net proceeds for product development activities, including clinical trials for its lead candidate TTX-MC138, and for working capital. ThinkEquity is acting as the sole placement agent for this offering, which is being conducted under a shelf registration statement filed with the SEC.

TransCode Therapeutics (Nasdaq: RNAZ), a clinical-stage RNA oncology company, has announced a proposed public offering of common stock and pre-funded warrants. The offering, managed by ThinkEquity as the sole placement agent, aims to raise funds for product development activities, including clinical trials for TTX-MC138, their lead therapeutic candidate. The company plans to use the proceeds for IND enabling studies, working capital, and general corporate purposes.

The securities will be offered through a shelf registration statement filed with the SEC. TransCode focuses on treating metastatic disease using RNA therapeutics based on its TTX nanoparticle platform. Their lead candidate targets tumors overexpressing microRNA-10b, a biomarker of metastasis.

TransCode Therapeutics (NASDAQ: RNAZ) has regained compliance with Nasdaq's listing standards, ensuring its stock remains on the exchange. The scheduled hearing for June 25, 2024, has been cancelled. The company will be monitored by Nasdaq until January 26, 2025. This compliance follows recent positive developments, including favorable blood test results from a Phase 0 clinical trial and FDA approval to proceed with a Phase 1 study. TransCode's leadership indicates that with the current share price above the $1.00 minimum bid, a reverse split is not anticipated.

TransCode Therapeutics (NASDAQ: RNAZ) announced positive preliminary data from its Phase 0 clinical trial for TTX-MC138, their lead RNA-based therapeutic candidate. The trial showed significant inhibition of the molecular target miRNA-10b, with a 66% reduction in the patient's blood 24 hours post-administration. This inhibition is linked to complete regressions of metastatic disease in animal models. The study also revealed effective delivery of TTX-MC138 to metastatic tumors and no adverse events were observed, indicating the treatment's safety at a microdose. These findings support further clinical development, with a Phase 1 study planned to explore TTX-MC138's potential for treating multiple metastatic cancers.

TransCode Therapeutics issued an open letter to shareholders regarding a proposed reverse split of their stock due to not meeting the Minimum Bid Requirement. The company faces potential delisting from Nasdaq but intends to appeal the decision. They believe a reverse split is the best chance to maintain Nasdaq listing. The Board and Management express their reluctance but emphasize the importance of shareholder support.